Investigators hope that their findings will assist in the development of targeted treatments for pediatric brain cancers.
This review explores the current literature on SRS treatment for both metastatic and benign intradural tumors, with a focus on differential use for intramedullary and intradural extramedullary neoplasms.
In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
This review explores commonly used experimental models of GBM, recent improvements to these models and strategies for developing advanced models.
New study demonstrates how the enzyme, ACSS2, contributes to brain tumor growth in environments scarce of oxygen and nutrients.
A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
The article reviews current literature on the use of adoptive immunotherapy for malignant gliomas as well as the
the concept of antitumor activity mediated by CIK cells.
A large, multicenter, genome-wide association study has identified a number of new genetic risk loci for malignant brain tumors.